COMPOUND

Compounds / Bioregulators

Livagen

Livagen (Lys-Glu-Asp-Ala / KEDA Tetrapeptide)

Bioregulators SubQ · Oral Not FDA approved

Khavinson family bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Synthetic tetrapeptide marketed as a hepatic / liver bioregulator, derived from analysis of Cortexin and liver tissue extracts. Most efficacy data is from one Russian lab; independent Western replication is essentially absent. Sequence is KEDA (Lys-Glu-Asp-Ala), vendor-confirmed, despite some legacy reference docs listing it as 'AEDK' (transposition error).

At a glance

Routes
SubQ · Oral
Vial sizes
20 mg
Evidence base
2 studies 2 preclinical

Mechanism

Per the Khavinson 'short-peptide bioregulator' hypothesis, KEDA is proposed to enter hepatocytes and bind specific DNA promoter regions, modulating expression of liver-specific genes. Mechanism is contested in mainstream pharmacology because tetrapeptides are normally degraded in serum within minutes. Reported in vitro effects: increased protein synthesis in aged rat hepatocyte cultures (toward young-rat levels) at nanomolar concentrations, restoration of intracellular circadian biosynthesis rhythms, heterochromatin → euchromatin conversion in lymphocytes.

Dosing

No standardized human dosing has been established. Every catalogued study for Livagen is preclinical or a literature review. Amounts used in animal models do not translate directly to humans.

Published evidence

  1. In vitro 2008

    Tetrapeptide KEDA stimulates protein synthesis in aged rat hepatocytes

    Khavinson VK et al. Bull Exp Biol Med

    Nanomolar Livagen restored protein synthesis rate in aged hepatocyte cultures toward levels of young animals.

  2. In vitro 2007

    Effects of short peptides on chromatin in lymphocyte cultures from aged donors (KEDA / Livagen)

    Khavinson VK, Lezhava TA, et al. Bull Exp Biol Med

    Livagen induced heterochromatin decondensation in cultured lymphocytes from aged donors, restoring transcriptional activity markers toward young phenotype.

Reported side effects

Long-term safety unverified outside Russia
Unknown Mild · Khavinson group reports no significant AEs in preclinical / limited clinical observation; small samples and no Western replication.

Interactions

  • Pancragen Synergy

    Hepatic + pancreatic axis; common Khavinson 'metabolic stack.'

Reconstitution and storage

20 mg vial; 2-5 mL BAC water. At 4 mg/mL, 100 mcg = 0.025 mL.

Lyophilized: room temp short-term, refrigerate for >30 days. Reconstituted: refrigerate, use within 30 days.

Open the reconstitution calculator for Livagen